Sheha Hosam, Tighe Sean, Hashem Omar, Hayashida Yasutaka
Department of Ophthalmology, Manhattan Eye, Ear & Throat Hospital, Northwell Health, New York, NY, USA.
Department of Ophthalmology, Florida International University Herbert Wertheim College of Medicine, Miami, FL, USA.
Clin Ophthalmol. 2019 Oct 7;13:1973-1980. doi: 10.2147/OPTH.S185184. eCollection 2019.
Neurotrophic keratitis is an underdiagnosed degenerative condition induced by impairment to the corneal nerves which may lead to persistent epithelial defects and corneal blindness. Current medical and surgical treatments are only supportive and poorly tackle the underlying problem of corneal anesthesia; hence, fail to provide a permanent cure. Cenegermin is a newly introduced recombinant human nerve growth factor (rhNGF) that may address this issue. Preliminary clinical trials have demonstrated the safety and efficacy of topical cenegermin in patients with moderate to severe neurotrophic keratitis; however, the clinical experience with this drug is still limited. This review summarizes the pathogenesis and management of neurotrophic keratitis as well as the mechanism of action, uses, and limitations of cenegermin eye drops in the treatment of neurotrophic keratitis.
神经营养性角膜炎是一种诊断不足的退行性疾病,由角膜神经损伤引起,可导致持续性上皮缺损和角膜盲。目前的药物和手术治疗仅起支持作用,难以解决角膜麻醉这一根本问题,因此无法提供永久性治愈。西奈吉明是一种新引入的重组人神经生长因子(rhNGF),可能解决这一问题。初步临床试验已证明局部应用西奈吉明治疗中重度神经营养性角膜炎患者的安全性和有效性;然而,这种药物的临床经验仍然有限。本综述总结了神经营养性角膜炎的发病机制和治疗方法,以及西奈吉明滴眼液在治疗神经营养性角膜炎中的作用机制、用途和局限性。